Time to Go Short on Pfizer (PFE)?

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 Value Index, which returned 3.79% for the same period. The fund’s top 5 holdings are also listed in the letter, showing the firm’s main investment positions heading into 2025.

One of the companies mentioned in the letter is Pfizer Inc. (NYSE:PFE). Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. Over the past month, Pfizer Inc. (NYSE:PFE) fell by -4.03%, and its shares lost -20.43% of their value over the last 12 months. On July 29, 2025, Pfizer Inc. (NYSE:PFE) shares closed at $24.30, with a market capitalization of $138.154 billion.

Here is what they have to say about Pfizer Inc. (NYSE:PFE) in their investor letter:

"Pfizer Inc. (NYSE:PFE) moved lower amid growing regulatory headwinds and several trial setbacks, including an oral GLP-1 drug. We exited our position in Pfizer due to reduced conviction in its turnaround thesis. This was driven by a weaker research and development pipeline following recent trial setbacks, including an oral GLP-1 drug, as well as increased likelihood of large merger and acquisition activities that could raise leverage amid growing regulatory and tariff headwinds.

Pfizer Inc. (NYSE:PFE) is not included in our list of the 30 most popular stocks among hedge funds. According to our data, 99 hedge fund portfolios held positions in Pfizer Inc. (NYSE:PFE) at the end of the first quarter of 2025, up from 92 in the previous quarter. Pfizer Inc. exceeded Q1 2025 earnings forecasts, posting EPS of $0.92 compared to the expected $0.666. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Pfizer Inc. (NYSE:PFE) is not included in our list of the 30 most popular stocks among hedge funds. According to our data, 99 hedge fund portfolios held positions in Pfizer Inc. (NYSE:PFE) at the end of the first quarter of 2025, up from 92 in the previous quarter. Pfizer Inc. exceeded Q1 2025 earnings forecasts, posting EPS of $0.92 compared to the expected $0.666. While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Pfizer Inc. (NYSE:PFE) and Jim Cramer’s views on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.